We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
+10.56%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$1.98B
AUM Growth
+$247M
Cap. Flow
+$143M
Cap. Flow %
7.22%
Top 10 Hldgs %
27.18%
Holding
159
New
18
Increased
48
Reduced
15
Closed
10

Top Buys

Rank Stock Value
1
MDT icon
Medtronic
MDT
+$33.7M
2
UNH icon
UnitedHealth
UNH
+$26.1M
3
AET
Aetna Inc
AET
+$23.7M
4
MRSN
Mersana Therapeutics
MRSN
+$21.1M
5
TMO icon
Thermo Fisher Scientific
TMO
+$18.5M

Top Sells

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$27.3M
2
SHPG
Shire pic
SHPG
+$24.2M
3
BMY icon
Bristol-Myers Squibb
BMY
+$21.9M
4
AMGN icon
Amgen
AMGN
+$16.1M
5
PTHN
Patheon N.V.
PTHN
+$10.5M

Sector Composition

Rank Sector Weight
1 Healthcare 79.63%
2 Financials 3.78%
3 Consumer Discretionary 1.13%
4 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALDR
126
DELISTED
Alder Biopharmaceuticals
ALDR
$2.08M 0.11%
182,000
– –
SYRE icon
127
Spyre Therapeutics
SYRE
$9.12B
$2.01M 0.1%
20,964
– –
NVDQ
128
DELISTED
Novadaq Technologies Inc.
NVDQ
$1.76M 0.09%
150,000
-405,000
-73% -$3.2M
MYOV
129
DELISTED
Myovant Sciences Ltd.
MYOV
$1.75M 0.09%
150,000
– –
ATYR
130
aTyr Pharma
ATYR
$49.2M
$1.61M 0.08%
33,929
– –
DVAX
131
DELISTED
Dynavax Technologies
DVAX
$1.59M 0.08%
165,000
– –
ALPN
132
DELISTED
Alpine Immune Sciences Inc
ALPN
$1.45M 0.07%
150,000
– –
SCYX icon
133
SCYNEXIS
SCYX
$51.6M
$1.36M 0.07%
9,500
– –
NVAX icon
134
Novavax
NVAX
$1.27B
$943K 0.05%
41,000
– –
PRGO icon
135
Perrigo
PRGO
$1.74B
$740K 0.04%
9,800
-5,800
-37% -$416K
CHMA
136
DELISTED
Chiasma, Inc. Common Stock
CHMA
$714K 0.04%
492,500
– –
EGLT
137
DELISTED
Egalet Corporation
EGLT
$711K 0.04%
300,000
– –
LUMO
138
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
$533K 0.03%
8,056
+604
+8% +$74.8K
OREX
139
DELISTED
Orexigen Therapeutics, Inc.
OREX
$479K 0.02%
165,300
– –
TNDM icon
140
Tandem Diabetes Care
TNDM
$1.29B
$450K 0.02%
56,250
-3,250
-5% -$30K
INFI
141
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$424K 0.02%
270,000
– –
DMTX
142
DELISTED
Dimension Therapeutics, Inc
DMTX
$393K 0.02%
271,370
– –
DARE icon
143
Dare Bioscience
DARE
$19.9M
$276K 0.01%
5,208
– –
ANTH
144
DELISTED
Anthera Pharmaceuticals, Inc.
ANTH
$268K 0.01%
165,705
+3,634
+2% +$8.15K
AMGN icon
145
Amgen
AMGN
$219B
– –
-98,000
Closed -$16.1M
BHC icon
146
Bausch Health
BHC
$2.21B
– –
-66,400
Closed -$732K
LGND icon
147
Ligand Pharmaceuticals
LGND
$6.02B
– –
-80,150
Closed -$5.29M
LLY icon
148
Eli Lilly
LLY
$1.06T
– –
-325,000
Closed -$27.3M
NVCR icon
149
NovoCure
NVCR
$1.83B
– –
-214,316
Closed -$1.74M
TVRD
150
Tvardi Therapeutics
TVRD
$23.1M
– –
-4,167
Closed -$2.76M
3 4 5
6
7

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.68B AUM 21.72% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return

Rock Springs Capital Management's Q2 2017 Portfolio in Review

As of Q2 2017, Rock Springs Capital Management held 159 positions worth $1.98B, up 14% from $1.73B the previous quarter. Its ten largest holdings account for 27% of the portfolio.

Rock Springs Capital Management deployed $143M of net new capital in Q2 2017, opening 18 new positions and adding to 48 existing holdings. Its largest new stake was Medtronic: 400,000 shares worth $35.5M.

By sector, the portfolio is most concentrated in Healthcare at 80% of assets, down from 82% a quarter earlier, followed by Financials and Consumer Discretionary.

On the sell side, the largest reduction was Bristol-Myers Squibb, an estimated $21.9M trimmed.

  • Rock Springs Capital Management's largest Q2 2017 buy was Medtronic: 400,000 shares worth $35.5M.
  • Rock Springs Capital Management added most to UnitedHealth in Q2 2017, an estimated $26.1M increase.
  • Rock Springs Capital Management's biggest Q2 2017 reduction was Bristol-Myers Squibb, cutting an estimated $21.9M.
  • Rock Springs Capital Management fully exited Eli Lilly in Q2 2017, selling an estimated $27.3M.
  • Rock Springs Capital Management's ten largest holdings make up 27% of its $1.98B portfolio in Q2 2017.
  • Rock Springs Capital Management opened 18 new positions and closed 10 in Q2 2017.
  • Rock Springs Capital Management's portfolio value rose 14% quarter-over-quarter to $1.98B.

Based on Rock Springs Capital Management's 13F filing for Q2 2017, filed 14 Aug 2017.